Search

Jeff S Himawan

from San Jose, CA
Age ~59
Get Report
Also known as:
Jeff Sugita Himawan, Jeff N Himawan, Jeffrey S Himawan, Jeff N
Phone and address:
5803 Killarney Cir, San Jose, CA 95138
(949) 498-6396
Related to:
Dawn M Bennett, 39
Connected to:
Andrew Himawan, 40Ridwan Himawan, 58Ryan H Himawan, 36Dennis G Himberger, 55Farran E Himberg, 41Bruce B Himbert, 33Sherlou F Himbing, 39Randy F Himburg, 58Aaron K Himchak, 39William Himchak, 56

Jeff Himawan Phones & Addresses

  • 5803 Killarney Cir, San Jose, CA 95138 (949) 498-6396
  • 5221 Nice Ct, San Jose, CA 95138
  • San Clemente, CA
  • 9654 Gretna Green Dr, Tampa, FL 33626
  • 617 Island Place Way, Tampa, FL 33602
  • Lincoln, MA
  • New York, NY
  • Bronx, NY
  • Jersey City, NJ
  • Centreville, VA

Business Records

Name / Title
Company / Classification
Phones & Addresses
Jeff Himawan
335 Bryant Associates, LLC
Rental of Commercial Real Estate · Management Consulting Services · Nonclassifiable Establishments
335 Bryant St, Palo Alto, CA 94301

Publications

Us Patents

Method Of Producing Biospecific Molecules By Protein Trans-Splicing

View page
US Patent:
20040077842, Apr 22, 2004
Filed:
Nov 3, 2003
Appl. No.:
10/415840
Inventors:
Jeff Himawan - Tampa FL, US
International Classification:
C07K016/28
C12P021/04
US Classification:
530/388220, 435/070210
Abstract:
The invention provides methods of using protein trans-splicing for the production of bispecific molecule which has a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds an antigenic molecule present in the circulatory system of a mammal. The invention also provides bispecific molecules produced by protein trans-splicing. The bispecific molecules of the invention can be used for the clearance of pathogenic antigenic molecules from the circulatory system of a mammal. The invention further provides methods of using protein trans-splicing for the production of polyclonal libraries of bispecific molecules, which comprise populations of bispecific molecules with different antigen recognition specificities. Such polyclonal libraries of bispecific molecules can be used for targeting multiple epitopes of a pathogenic antigenic molecule and/or multiple variants of a pathogenic antigenic molecule.

Bispecific Molecules And Uses Thereof

View page
US Patent:
20040180046, Sep 16, 2004
Filed:
Mar 3, 2004
Appl. No.:
10/258650
Inventors:
Jeff Himawan - Tampa FL, US
International Classification:
A61K039/395
C07K016/44
US Classification:
424/132100, 530/387300
Abstract:
The present invention relates to bispecific molecules that are characterized by having a first binding domain which binds an antigen present in the circulation of a mammal and a second binding domain which binds the C3b-like receptor (known as complement receptor 1 (CR1) or CD35 in primates). The bispecific molecules do not consist of a first monoclonal antibody to CR1 that has been chemically cross-linked to a second monoclonal antibody. The invention also relates to methods of making the bispecific molecules and therapeutic uses thereof, as well as to kits containing the bispecific molecules. The invention further provides polyclonal populations of bispecific molecules, which comprise populations of bispecific molecules with different antigen recognition specificities. Such polyclonal populations of bispecific molecules can be used for targeting multiple epitopes of a pathogenic antigenic molecule and/or multiple variants of a pathogenic antigenic molecule.

Polyclonal Populations Of Bispecific Molecules And Methods Of Production And Uses Thereof

View page
US Patent:
20040234521, Nov 25, 2004
Filed:
Jun 17, 2004
Appl. No.:
10/472051
Inventors:
Jeff Himawan - San Jose CA, US
Assignee:
Elusys Therapeutics, Inc
International Classification:
A61K039/395
C07K016/28
US Classification:
424/144100, 530/388220
Abstract:
The invention relates to a polyclonal population of bispecific molecules which comprises a plurality of different bispecific molecules, each comprising a first antigen recognition portion that binds a C3b-like receptor cross-linked to a different second antigen recognition portion that binds a pathogenic antigenic molecule such that the plurality of different bispecific molecules have different second antigen recognition portions with different recognition specificities, such as with recognition specificities directed to different epitopes and/or different variants of a pathogen and/or to different pathogens. The invention also relates to methods of producing such polyclonal population of bispecific molecules. The invention further relates to methods of using such polyclonal population of bispecific molecules for the clearance of pathogens from the circulatory system of a mammal.

Immunogenicity-Reduced Anti-Cr1 Antibody And Compositions And Methods Of Treatment Based Thereon

View page
US Patent:
20070224196, Sep 27, 2007
Filed:
Mar 29, 2004
Appl. No.:
10/551525
Inventors:
Jeff Himawan - San Jose CA, US
Anita Hamilton - Aberdeen, GB
Francis Carr - Cambridge, GB
Assignee:
EluSys Therapeutics, Inc. - Pine Brook NJ
International Classification:
A61K 48/00
A61K 31/70
A61K 39/395
C12N 5/06
C07K 16/28
US Classification:
424144100, 530388220, 435334000, 514044000
Abstract:
The invention provides immunogenicity-reduced antibodies or antibody fragments that bind a human CR1 receptor. The immunogenicity-reduced anti-CR1 antibody of the invention comprises one or more non-human sequences modified to comprise one or more amino acid substitutions so that the immunogenicity-reduced antibody id non-immunogenic or less immunogenic to a human. The invention also provides bispecific molecules comprising such an immunogenicity-reduced anti-CR1 antibody and an antigen-recognition portion that binds a pathogen. The invention further provides methods and compositions for the treatment of diseases or disorders caused by a blood-borne immunogenic pathogen using the bispecific molecule the invention of the invention.
Control profile
Jeff S Himawan from San Jose, CA, age ~59 Get Report